Gillian D. Sanders, PhD; Ahmed M. Bayoumi, MD, MSc; Mark Holodniy, MD; Douglas K. Owens, MD, MS
Although many older adults have HIV infection, national guidelines recommend screening only persons age 13 to 64 years. Using a decision model, Sanders and colleagues examined the costs and benefits of HIV screening in patients age 55 to 75 years. Screening is reasonably cost-effective when HIV prevalence is 0.1% or greater, the counseling process is streamlined, and the person has an at-risk partner. This information should inform decisions about expanding screening recommendations to older people.
Ann Intern Med. 2008;148(12):889-903. doi:10.7326/0003-4819-148-12-200806170-00002
Esther Lopez-Garcia, PhD; Rob M. van Dam, PhD; Tricia Y. Li, MD; Fernando Rodriguez-Artalejo, MD, PhD; Frank B. Hu, MD, PhD
Studies have examined the association between coffee consumption and a variety of specific diseases, but the relationship between coffee consumption and all-cause mortality remains unclear. This study followed 2 large cohorts of men and women who had provided data on coffee consumption, other behaviors, and health outcomes every 2 to 4 years over 2 decades. High coffee consumption was not related to increased mortality and may be associated with lower total and cardiovascular mortality, a finding that requires further investigation.
Ann Intern Med. 2008;148(12):904-914. doi:10.7326/0003-4819-148-12-200806170-00003
Ateev Mehrotra, MD, MPH; Lori Keehl-Markowitz, RN, BSN; John Z. Ayanian, MD, MPP
Mehrotra and colleagues helped 6 primary care practices implement open-access scheduling, in which patients receive an appointment at or near the time of their choosing. Five of the 6 practices substantially reduced waiting times for appointments, but none could consistently provide same-day access or sustain shorter waiting times. Patient and staff satisfaction did not change, no-show rates remained the same, and the practices differed too much to measure postimplementation changes in average waiting time.
Ann Intern Med. 2008;148(12):915-922. doi:10.7326/0003-4819-148-12-200806170-00004
Nadim S. Jafri, MD, MSc; Carlton A. Hornung, PhD, MPH; Colin W. Howden, MD
Sequential provision of antibiotics may help overcome the declining efficacy of treatment for Helicobacter pylori. In their review and meta-analysis, Jafri and colleagues compared sequential therapy with standard triple therapy for H. pylori infection. Among 10 trials, evidence consistently favored sequential over standard triple therapy for H. pylori. However, most trials were performed in 1 country (Italy), 1 trial was performed in children only, and the investigators found strong evidence for publication bias.
Ann Intern Med. 2008;148(12):923-931. doi:10.7326/0003-4819-148-12-200806170-00226
Otis W. Brawley, MD; Llewellyn J. Cornelius, PhD, LCSW; Linda R. Edwards, MD; Vanessa Northington Gamble, MD, PhD; Bettye L. Green, RN; Charles Inturrisi, PhD; Andra H. James, MD, MPH; Danielle Laraque, MD; Magda Mendez, MD; Carolyn J. Montoya, RN, MSN, CPNP; Brad H. Pollock, MPH, PhD; Lawrence Robinson, MD, MPH; Aaron P. Scholnik, MD; Melissa Schori, MD, MBA
Hydroxyurea has benefited some patients with sickle cell disease—an inherited blood disorder that affects 50 000 to 100 000 people in the United States—but several issues about its use are unresolved. To more closely examine this topic, the National Heart, Lung, and Blood Institute and the Office of Medical Applications of Research of the National Institutes of Health convened a Consensus Development Conference to assess the available scientific evidence. This article answers key questions about the evidence.
Ann Intern Med. 2008;148(12):932-938. doi:10.7326/0003-4819-148-12-200806170-00220
Sophie Lanzkron, MD; John J. Strouse, MD; Renee Wilson, MSc; Mary Catherine Beach, MD, MPH; Carlton Haywood, MA; HaeSong Park, MD, MPH; Catherine Witkop, MD, MPH; Eric B. Bass, MD, MPH; Jodi B. Segal, MD, MPH
Lanzkron and colleagues synthesized the evidence on the efficacy, effectiveness, and toxicity of hydroxyurea for treating adults with sickle cell disease. They found that hydroxyurea increases fetal hemoglobin in adults with sickle cell disease and reduces the frequency of pain crises, hospital-days, and transfusions. They found far less evidence on hydroxyurea's effect on hospitalization, stroke, pain crises, the acute chest syndrome, and death outcomes. Limited evidence indicated that hydroxyurea treatment of sickle cell disease is not associated with leukemia or leg ulcers. The evidence was insufficient to estimate the risk for skin neoplasms.
Ann Intern Med. 2008;148(12):939-955. doi:10.7326/0003-4819-148-12-200806170-00221
American College of Physicians
The American College of Physicians recently highlighted the need for increased information on the comparative effectiveness of health care interventions and recommended the establishment of an adequately funded, trusted national entity to prioritize, sponsor, or produce both comparative clinical and cost-effectiveness data. This article addresses the need for the proposed entity to develop cost-effectiveness information. It examines the current reluctance to develop and use cost-effectiveness in the United States, arguing for the importance of this information for all health care stakeholders, and recommending how to disseminate and use this information.
Ann Intern Med. 2008;148(12):956-961. doi:10.7326/0003-4819-148-12-200806170-00222
Barry Marshall, MD
In sequential therapy for H. pylori, more antibiotics are added to the treatment regimen in sequence rather than giving all 4 drugs together. In this issue, Jafri and colleagues' meta-analysis of clinical trials of sequential therapy convincingly confirms the efficacy of sequential therapy for H. pylori. Marshall describes several reasons why this therapeutic strategy makes sense.
Ann Intern Med. 2008;148(12):962-963. doi:10.7326/0003-4819-148-12-200806170-00227
Alan M. Garber, MD, PhD
Commenting on American College of Physicians' position paper, which contends that cost-effectiveness analysis should be linked to any study of clinical effectiveness, Garber discusses how comparative effectiveness research can fill part of the information void.
Ann Intern Med. 2008;148(12):964-966. doi:10.7326/0003-4819-148-12-200806170-00223
Gail R. Wilensky, PhD
As a counterpoint to the College's position, Wilensky (despite general agreement that cost-effectiveness information should be used to develop smarter strategies of reimbursement) believes keeping comparative clinical effectiveness analysis and cost-effectiveness analysis separate from each other to be vitally important.
Ann Intern Med. 2008;148(12):967-968. doi:10.7326/0003-4819-148-12-200806170-00224
Ann Intern Med. 2008;148(12):969. doi:10.7326/0003-4819-148-12-200806170-00012
Ann Intern Med. 2008;148(12):969-970. doi:10.7326/0003-4819-148-12-200806170-00013
Ann Intern Med. 2008;148(12):970. doi:10.7326/0003-4819-148-12-200806170-00014
Ann Intern Med. 2008;148(12):970-971. doi:10.7326/0003-4819-148-12-200806170-00015
Dirk Bassler, MD, MSc; Jason W. Busse, DC, MSc; Paul J. Karanicolas, MD, PhD; Gordon H. Guyatt, MD, MSc
Ann Intern Med. 2008;148(12):JC4-2. doi:10.7326/0003-4819-148-12-200806170-02002
David Tong, MD, FAHA
Ann Intern Med. 2008;148(12):JC4-3. doi:10.7326/0003-4819-148-12-200806170-02003
Deborah Cook, MD; Lauralyn McIntyre, MD
Ann Intern Med. 2008;148(12):JC4-4. doi:10.7326/0003-4819-148-12-200806170-02004
Randolph J. Lipchik, MD
Ann Intern Med. 2008;148(12):JC4-5. doi:10.7326/0003-4819-148-12-200806170-02005
Francois Lamontagne, MD, MSc; Maureen O. Meade, MD, MSc
Ann Intern Med. 2008;148(12):JC4-6. doi:10.7326/0003-4819-148-12-200806170-02006
David P. Steensma, MD
Ann Intern Med. 2008;148(12):JC4-7. doi:10.7326/0003-4819-148-12-200806170-02007
Orly Kohn, MD
Ann Intern Med. 2008;148(12):JC4-8. doi:10.7326/0003-4819-148-12-200806170-02008
John K. Marshall, MD, MSc, FRCPC, AGAF
Ann Intern Med. 2008;148(12):JC4-9. doi:10.7326/0003-4819-148-12-200806170-02009
Andrew Dunn, MD, FACP
Ann Intern Med. 2008;148(12):JC4-10. doi:10.7326/0003-4819-148-12-200806170-02010
A. Niro Siriwardena, MBBS, MMedSci, PhD
Ann Intern Med. 2008;148(12):JC4-11. doi:10.7326/0003-4819-148-12-200806170-02011
David Tong, MD
Ann Intern Med. 2008;148(12):JC4-12. doi:10.7326/0003-4819-148-12-200806170-02012
Raj Padwal, MD
Ann Intern Med. 2008;148(12):JC4-13. doi:10.7326/0003-4819-148-12-200806170-02013
Christopher B. Granger, MD
Ann Intern Med. 2008;148(12):JC4-14. doi:10.7326/0003-4819-148-12-200806170-02014
Ann Intern Med. 2008;148(12):I-40. doi:10.7326/0003-4819-148-12-200806170-00001
Donald H. Rubin, MD
Ann Intern Med. 2008;148(12):972. doi:10.7326/0003-4819-148-12-200806170-00016
Ashwini R. Sehgal, MD
Ann Intern Med. 2008;148(12):972. doi:10.7326/0003-4819-148-12-200806170-00017
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only